Brief: PCI Biotech extends existing collaboration agreement

PCI Biotech Holding ASA

14/12/2016 06:09

Dec 14(Reuters) - PCI Biotech Holding ASA  PCIB.OL : 
    * Said on Tuesday an undisclosed pharma company intend to extend the existing research 
collaboration agreement, originally signed in Sept. 2015, until the end of Q2 2017 
    * Aim is to further evaluate the synergistic effects of both parties' technology platforms, 
to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the 
therapeutic effect of the partner's nucleic acid therapeutic compounds 
    * Pre-clinical research agreement to cover evaluation of technological compatibility  and 
synergy based on in vitro studies 
    * The pharma company specializes in nucleic acid therapeutics and is responsible for funding 
and conducting the research 
 
     
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE4Nx8bp 
     
 Further company coverage:  PCIB.OL   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))